Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: Equal efficacy of lymphocytes from sibling and matched unrelated donors

Bone Marrow Transplantation

Volumn 21, Issue 10, 1998, Pages 1055-1061

  Van Rhee, F ^a,b   Savage, D ^a   Blackwell, J ^a   Orchard, K ^a   Dazzi, F ^a   Lin, F ^a   Chase, A ^a   Bungey, J ^a   Cross, N C P ^a   Apperley, J ^a   Szydlo, R ^a   Goldman, J M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; BMT; CML; DLT; Unrelated donor

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LYMPHOCYTE TRANSFUSION; MALE; PRIORITY JOURNAL; PROBABILITY; RELAPSE;

EID: 0031775773     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701224     Document Type: Article

References (39)

1. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954-1956
2. Gratwohl A, Hermans J, Niederwieser D et al. Bone marrow transplantation for chronic myeloid leukemia: long term results. Bone Marrow Transplant 1993; 12: 509-516.
3. Clift RA, Storb R. Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant 1996; 17 (Suppl. 3): S1-S3.
4. Marks DI, Hughes TP, Szydlo R et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia: influence of GVHD prophylaxis on outcome. Br J Haematol 1992; 81: 383-390.
5. Forman SJ, JA Zaia. Review: treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand. Blood 1994; 83: 2392-2398.
6. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996; 17. (Suppl. 1): S5-S6.
7. Enright H, Davies S, DeFor T et al. Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukaemia: early transplantation, use of an unrelated donor and chronic graft-versus-host disease are protective. Blood 1996; 88: 714-720.
8. Kolb H-J, Mittermüller J, Clemm Ch et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
9. Drobyski W, Keever C, Roth M et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2318.
10. Bär BMAM, Schattenberg A, Mensink EJBM et al. Donor leukocyte infusions for chronic myeloid leukemia after allogeneic bone marrow transplantation. J Clin Oncol 1993; 11: 513-519.
11. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukaemia. New Engl J Med 1994; 330: 100-106.
12. Hertenstein B, Wiesneth M, Novotny J et al. Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 1993; 56: 1114-1118.
13. Helg C, Roux E, Beris P et al. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1995; 12: 125-129.
14. Porter D, Roth MS, Lee SJ et al. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 18: 975-980.
15. Kolb H-J, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
16. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337-4343.
17. Collins R, PiÑeiro L, Nemunaitis J et al. Donor buffy coat infusion in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. Transfusion 1995; 35: 891-898.
18. Mackinnon S, Papadopoulos E, Carabasi M et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
19. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant interleukin 2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
20. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. New Engl J Med 1993; 328: 593-602.
21. McGlave P, Bartsch G, Anasetti C et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: initial experience of the National Marrow Donor program. Blood 1993; 81: 543-550.
22. Speiser DE, Tiercy J-M, Rufer N et al. High resolution HLA matching associated with decreased mortality after unrelated marrow bone marrow transplantation. Blood 1996; 87: 4455-4462.
23. Marks DI, Cullis JO, Ward KN et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. Ann Int Med 1993; 119: 207-214.
24. Cross NCP, Hughes TP, Lin F et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 1993; 84: 67-74.
25. Cross NCP, Lin F, Chase A et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia after bone marrow transplantation. Blood 1993; 82: 1929-1936.
26. Thomas ED, Storb R, Clift R et al. Bone marrow transplantation. New Engl J Med 1975; 292: 832-843, 895-902.
27. Shulman HM, Sullivan KM, Weiden P et al. Chronic graft-versus-host-disease syndrome in man. A long term clinico-pathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
28. van Rhee F, Feng L, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3383.
29. Drobyski WR, Ash RC, Casper JT et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukaemia. Blood 1994; 83: 1980-1987.
30. Hessner M, Endean D, Casper J et al. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995; 86: 3987-3996.
31. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
32. Goldman JM, Gale RP, Horowitz M et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
33. Ferster A, Bujan W, Mouraux T et al. Complete remission following donor leukocyte transfusion after haplo-identical bone marrow transplantation. Bone Marrow Transplant 1994; 14: 331-332.
34. Pati AR, Godder K, Lamb L et al. Immunotherapy with donor leukocyte transfusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 1995; 15: 979-981.
35. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte transfusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplatation. J Clin Oncol 1997; 15: 433-444.
36. Miyamura K, Tanimoto M, Horibe K et al. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood 1992; 79: 1366-1370.
37. Radich JP, Gehly G, Gooley T et al. Polymerase chain-reaction detection of the bcr-abl fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia - results and implications in 346 patients. Blood 1995; 85: 2632-2638.
38. Gaiger A, Lion T, Kahls P et al. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT). Leukemia 1993; 7: 1766-1772.
39. Heslop HE, Ng YC, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med 1996; 2: 551-555.